Bill Radvak is Executive Chairman and Interim Chief Executive Officer of NervGen Pharma Corp., a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. He can be reached at [email protected]